media – Page 630 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

AbbVie Receives U.S. FDA Priority Review for Investigational Oral Treatment Elagolix for the Management of Endometriosis with Associated Pain

AbbVie, a research and development based global biopharmaceutical company in cooperation with Neurocrine Biosciences, Inc. , announced that the U.S. Food and Drug Administration (FDA) has granted priority review for elagolix, an investigational, orally administered gonadotropin-releasing hormone (GnRH) antagonist, being investigated for the management of endometriosis with associated pain.
- Source: news.abbvie
- 744
- November 2, 2017
antagonist biopharmaceutical GnRH New Approvals
Scientists discover 27 genes that could halt cancer

From an analysis of more than 2,000 tumors spanning 12 types of human cancer, scientists have identified 27 new genes that could stop the disease in its tracks.
- Source: medicalnewstoday
- 686
- November 2, 2017
cancer Researches suppressor genes tumor
Wearable Devices–A New Look For The Modern Clinical Trial

Clinical development has historically been a laborious and expensive process that stretches across all therapeutic areas. It is driven by lengthy patient recruitment timelines, increasingly complex study designs, and high procedural costs. Depending on whose data you believe, getting a new drug to market can now cost upwards of $1 billion and take more than 10 years or research and development effort. Additionally, a complex and dynamic regulatory framework has made sponsors reluctant to introduce new technologies to facilitate the development process.
- Source: clinicalleader
- 995
- November 2, 2017
Artificial Intelligence Clinical machine learning Researches wearables
Flu Vax May Improve Outcomes in Other Illnesses

Even when the flu vaccine doesn't prevent disease, it can ease some of the consequences, researchers said here.
- Source: medpagetoday
- 845
- November 2, 2017
disease flu Researches vaccine
Joining ICH–Opportunity or Challenge?

Ddu has gradually made its way through Europe by attending the CPhI Worldwide 2017 in Frankfurt and Medica 2017 in Düsseldorf, Germany. During conversations with manufacturers, ICH was frequently mentioned. Since China was admitted as one of the regulatory members of ICH in June of last year, it was now placed at the forefront of the discussions.
- Source: drugdu
- 740
- November 2, 2017
Ddu College EC FDA ICH MHLW PMDA
AstraZeneca Plots Crucial IDO Phase III Combo Trial With Incyte

AstraZeneca and Incyte Corporation are pushing forward on the development of immunotherapy combination treatments.
- Source: Cnbc
- 442
- November 2, 2017
AstraZeneca immunotherapy combination
Innovative heart device is safe and effective, study finds

A new study has found that a pioneering device to repair heart valves is safe and effective, and can reduce the invasiveness and side effects of conventional mitral valve surgery.
- Source: Medicalxpress
- 803
- November 2, 2017
Harpoon Mitral Valve Repair System heart valves
Latest Updates on GMP in Thailand

Thailand may be one of the countries that pose the biggest challenge for companies who would like to register their pharmaceutical products in Southeast Asia since they require more than your standard documents.
- Source: Ddu
- 1,039
- November 2, 2017
Ddu College GMP register standard documents Thailand
Novartis pivotal data show children and adolescents with relapsing MS had an 82% lower relapse rate with fingolimod vs. interferon beta-1a

Novartis announced results from the Phase III PARADIGMS study, investigating the safety and efficacy of fingolimod vs. interferon beta-1a, in children and adolescents (ages 10 to <18) with relapsing multiple sclerosis (MS).
- Source: Prnewswire
- 673
- November 1, 2017
Clinical Trial Phase relapsing multiple sclerosis
FDA approves new treatment for adults with mantle cell lymphoma

The U.S. Food and Drug(FDA) Administration today granted accelerated approval to Calquence (acalabrutinib) for the treatment of adults with mantle cell lymphoma who have received at least one prior therapy.
- Source: Prnewswire
- 794
- November 1, 2017
Calquence FDA mantle cell lymphoma New Approvals

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.